PZRXQ.US PhaseRx Inc

Healthcare Biotechnology USA Stocks
0.0001 USD
Close of Nov 17, 2026
0.0001 0.0001
Market cap
USD 1.17K
P/E
-
P/B
3.25x
ROE
-
Dividend yield
-
Fundamental score
-

Is PZRXQ.US undervalued?

Graham number

The Graham number of PhaseRx Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

PhaseRx Inc fundamental analysis

No fundamental analysis for PhaseRx Inc yet.

PhaseRx Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About PhaseRx Inc

PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder programs under development include PRX-OTC to treat ornithine transcarbamylase deficien…

Full company profile